TNGX vs. PRAX, CALT, DAWN, ANIP, AUPH, SYRE, SPRY, SNDX, COLL, and ELVN
Should you be buying Tango Therapeutics stock or one of its competitors? The main competitors of Tango Therapeutics include Praxis Precision Medicines (PRAX), Calliditas Therapeutics AB (publ) (CALT), Day One Biopharmaceuticals (DAWN), ANI Pharmaceuticals (ANIP), Aurinia Pharmaceuticals (AUPH), Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Syndax Pharmaceuticals (SNDX), Collegium Pharmaceutical (COLL), and Enliven Therapeutics (ELVN). These companies are all part of the "pharmaceutical products" industry.
Tango Therapeutics vs.
Tango Therapeutics (NASDAQ:TNGX) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability, community ranking and analyst recommendations.
Tango Therapeutics currently has a consensus target price of $13.14, indicating a potential upside of 361.15%. Praxis Precision Medicines has a consensus target price of $146.33, indicating a potential upside of 107.45%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tango Therapeutics is more favorable than Praxis Precision Medicines.
Praxis Precision Medicines received 14 more outperform votes than Tango Therapeutics when rated by MarketBeat users. However, 73.68% of users gave Tango Therapeutics an outperform vote while only 72.41% of users gave Praxis Precision Medicines an outperform vote.
79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 6.3% of Tango Therapeutics shares are held by insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Praxis Precision Medicines had 3 more articles in the media than Tango Therapeutics. MarketBeat recorded 3 mentions for Praxis Precision Medicines and 0 mentions for Tango Therapeutics. Praxis Precision Medicines' average media sentiment score of 0.39 beat Tango Therapeutics' score of 0.00 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.
Tango Therapeutics has a net margin of -284.42% compared to Praxis Precision Medicines' net margin of -9,409.22%. Tango Therapeutics' return on equity of -49.64% beat Praxis Precision Medicines' return on equity.
Tango Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.
Tango Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.66, indicating that its share price is 166% more volatile than the S&P 500.
Summary
Tango Therapeutics beats Praxis Precision Medicines on 12 of the 17 factors compared between the two stocks.
Get Tango Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tango Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TNGX) was last updated on 1/20/2025 by MarketBeat.com Staff
Free TNGX Stock Alerts